Fundacio Privada Institutcio Catalana De Recerca I Estudis Avancats (icrea)

Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron

Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats

Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron

Fundacio Privada Institut De Recerca Hospital Universitatri Vall Hebron (ir-huvh)

Fundacio Privada Institucio Catalana De Recera I Estudis Avancats

Fundacio Privada Institut D'investigatio Oncologica Vall De'hebron (vhio)

Fundació Privada Institut D'investigatió Oncológica De Vall Hebron (Vhio)

Fundacio Privada Institut De Recerca Hospital Universitari Vall Hebron (ir-huvh)

Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron

Fundació Privada Institució Catalana De Recerca I Estudis Avançants

José Baselga Torres

Joan Seoane Suarez

Kim Pedersen

Pier-Davide Angellini

Silvia Penuelas Prieto

Joaquin Arribas Lopez

Sirle Laos

Josep Lluis Parra Palau

Josep Liuis Parra Palau

Joan Seoane Suárez

Silvia PEÑUELAS Prieto

Joaquín Arribas López

Josep Lluís Parra Palau

The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

The present invention relates to inhibitors of the expression and/or activity of LIF for the treatment of cancer. Particularly, the present invention provides an in vitro method for designing a customized therapy for a patient suffering from cancer comprising (a) quantifying the expression levels of LIF in said patient, and (b) comparing said expression levels with control levels, wherein if the expression levels of LIF in said patient are greater than the control values, then an inhibitory agent of LIF is administered to said patient.

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

Antibodies against HER2 truncated variant CTF-611

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

Method for diagnosing cancers expressing the HER2 receptor or its truncated variants

Growing community of inventors

Barcelona, Spain

José Baselga Torres